Published in Cancer Weekly, January 17th, 2006
The report indicates clinical and research progress and triggers the achievement of a milestone in Vertex's contractual collaboration with Merck & Co., Inc. to develop aurora kinase inhibitors for the treatment of cancer.
VX-680 is a small molecule inhibitor of aurora kinases and the lead development compound in the collaboration. In addition, Merck has selected a follow-on compound for development from a joint aurora kinase research program that is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.